Updated

The FDA granted an authorization expanding Philip Morris International's Zyn nicotine pouch business, a move seen as a potential growth driver for the company's smoke-free product portfolio. Analysts are weighing whether the expanded authorization can translate into meaningful revenue gains. The decision comes as Philip Morris continues to lean on Zyn as a key growth engine amid a broader industry shift away from traditional cigarettes toward alternative nicotine products.